To assess the tolerability of switching from Depakote Sprinkle Capsules or Depakote tablets to Depakote ER tablets in the pediatric population.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
16
Administered according to the subject's usual regimen.
Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
Unnamed facility
Richmond, Virginia, United States
Number of seizures
Time frame: 2 weeks
Number of Adverse Events
Time frame: 2 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.